NR4A1 and triple-negative breast carcinoma: Additionally, T-DXd is the first ADC approved for HER2-low metastatic breast cancer (IHC 1+ or 2+/ISH negative), particularly effective in hormone receptor-positive or triple-negative breast cancer, and is recommended for use after chemotherapy (19, 20).